Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | GALR3 | O60755 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15178086 | 1.00 | HIF1A (0.62) | HIF1ALMNAGALR3ADRB1ADRA1A | |
| SCHEMBL7458513 | 0.95 | LMNA (0.57) | HIF1ALMNAGALR3ADRB1ADRA1A | |
| SCHEMBL10360541 | 0.91 | HIF1A (0.60) | HIF1ALMNAGALR3ADRB1ADRA1A | |
| SCHEMBL9620888 | 0.89 | HIF1A (0.58) | HIF1ALMNAGALR3ADRB1ADRA1A | |
| SCHEMBL11593821 | 0.88 | LMNA (0.46) | HIF1ALMNAGALR3ADRB1ADRA1A | |
| SCHEMBL31094667 | 0.84 | LMNA (0.66) | HIF1ALMNAGALR3ADRB1ADRA1A | |
| SCHEMBL12610310 | 0.84 | LMNA (0.66) | HIF1ALMNAGALR3ADRB1ADRA1A | |
| SCHEMBL2978589 | 0.84 | LMNA (0.66) | HIF1ALMNAGALR3ADRB1ADRA1A | |
| SCHEMBL5563575 | 0.82 | HIF1A (0.50) | HIF1ALMNAGALR3ADRB1ADRA1A | |
| SCHEMBL11619633 | 0.82 | OPRM1 (0.54) | HIF1ALMNAGALR3ADRB1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216282-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | GALDERMA LABORATORIES INC | 2017-08-03 | — | — | US | disclosed |
| US-20170136013-A1 | Method of Treating Hand-Foot Syndrome and Symptoms Associated Therewith | GALDERMA S.A. (CH) | 2017-05-18 | — | — | US | disclosed |
| US-20160220565-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | Galderma Laboratories, L.P. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160166569-A1 | METHOD FOR TREATING SKIN THICKENING | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2016-06-16 | — | — | US | disclosed |
| US-20150374686-A1 | Methods of Treating Flushing Associated with Carcinoid Tumors and Carcinoid Syndrome | Galderma Holding SA (CH) | 2015-12-31 | — | — | US | disclosed |
| US-9186358-B2 | Combination therapy for treating or preventing an inflammatory skin disorder | Galderma Laboratories, L.P. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150313896-A1 | METHOD FOR TREATING CELL PROLIFERATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-11-05 | — | — | US | disclosed |
| US-20150202202-A1 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | Galderma Laboratories, L.P. (US) | 2015-07-23 | — | — | US | disclosed |
| US-9072739-B2 | Method for treating psoriasis | Galderma Laboratories, L.P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150098917-A1 | METHOD FOR PREVENTING OR TREATING SKIN TUMOR | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-04-09 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1991019475-A2 | QUINOLINYL-BENZOHETEROBICYCLIC DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1991-12-26 | — | — | WO | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0434827-A1 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-07-03 | — | — | EP | disclosed |
| WO-1991001123-A2 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| US-4977162-A | Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments | RORER PHARMACEUTICAL CORPORATION (US) | 1990-12-11 | — | — | US | disclosed |
| US-4920131-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989012628-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0348155-A1 | Quinoline derivatives as antagonists of leukotriene D4, compositions containing the same and processes for their preparation | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166569-A1 | METHOD FOR TREATING SKIN THICKENING | CUTA, EDNRB, TBXA2R | HIF1A 1582/4885LMNA 525/4885GALR3 42/4885 |
| US-20150098917-A1 | METHOD FOR PREVENTING OR TREATING SKIN TUMOR | ADRB2, ADRA2A, ADRA2C | HIF1A 560/4885LMNA 1555/4885GALR3 69/4885 |
| US-20150374686-A1 | Methods of Treating Flushing Associated with Carcinoid Tumors and Carcinoid Syndrome | MC2R, ADRA2C, ADRB2 | HIF1A 1552/4885LMNA 4315/4885GALR3 76/4885 |
| US-20150313896-A1 | METHOD FOR TREATING CELL PROLIFERATION DISORDERS | MKI67, ADRB1, ADRA1D | HIF1A 1840/4885LMNA 2170/4885GALR3 1385/4885 |
| US-20150202202-A1 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HRH4, HRH1, HRH3 | HIF1A 441/4885LMNA 3029/4885GALR3 439/4885 |
| US-20170216282-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | HIF1A 441/4885LMNA 3029/4885GALR3 439/4885 |
| US-20160220565-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | HIF1A 441/4885LMNA 3029/4885GALR3 439/4885 |
| US-20170136013-A1 | Method of Treating Hand-Foot Syndrome and Symptoms Associated Therewith | ADRB1, ADRA2A, ADRB2 | HIF1A 2105/4885LMNA 4026/4885GALR3 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.